New York, NY, October 18, 2023 (Globe Newswire) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) has named Michael Rossi as President and CEO, effective November 6, 2023. Rossi will also join the company's Board of Directors. Y-mAbs focuses on developing and commercializing antibody-based therapeutic products for cancer treatment.
Read full article here.
NY, NY, April 18, 2024 (Business Wire) -- Metsera, Inc., a pioneering player in the clinical-stage biopharmaceutical realm focusing on innovative treatments for obesity and metabolic ailments, has e
Cambridge, MA, April 23 2024 (PRNewswire) -- Flare Therapeutics Inc. has undergone a notable leadership transition with the selection of Dr. Douglas Manion, M.D., FRCP (C), as its newly appointed Ch
Wilmington, DE, April 23, 2024 (RTTNews) -- Incyte Corp. (INCY) is buying Escient Pharmaceuticals and its assets for $750 million, plus any cash left over when the deal closes. This acquisition need
